首页> 外国专利> COLD-ADAPTED-VIRAL-ATTENUATION (CAVA) AND NOVEL ATTENUATED POLIOVIRUS STRAINS

COLD-ADAPTED-VIRAL-ATTENUATION (CAVA) AND NOVEL ATTENUATED POLIOVIRUS STRAINS

机译:冷适应性病毒衰减(CAVA)和新型减毒脊髓灰质炎病毒株

摘要

Cold-Adapted-Viral-Attenuation (CAVA) and Novel Attenuated Poliovirus Strains A poliovirus (PV) strain was attenuated by a novel method of Cold-Adapted-Viral- Attenuation (CAVA). The resulting recombinant attenuated PV, CAVA-PV, shows wild- type replication at 30°C, but no substantial replication at 37°C. The inability to replicate at 37 °C is defined by an inability to quantify virus during infection at this temperture by titration (infectious units), qPCR (viral RNA) or Electron Microscopy (visual signs of infection). CAVA-PV is genetically stable under production conditions and shows utility for use as the backbone to produce attenuated strains with the same antigenic profile as conventional vaccines by replacing the sequence coding for the capsid of CAVA-PV with sequences coding for capsids of different PV strains. Furthermore, mutations identified in CAVA-PV can be engineered into different, even wild-type and neurovirulent poliovirus background strains to obtain additional CAVA-PV strains. No Suitable Figure
机译:冷适应病毒衰减(CAVA)和新型减毒脊髓灰质炎病毒株通过一种新型冷适应病毒衰减(CAVA)方法减毒了脊髓灰质炎病毒(PV)株。所得重组减毒PV,CAVA-PV,在30°C时显示野生型复制,但在37°C时没有实质性复制。在此温度下无法通过滴定(感染单位),qPCR(病毒RNA)或电子显微镜(可见感染迹象)量化感染过程中的病毒,从而定义了无法在37°C复制。 CAVA-PV在生产条件下在遗传上是稳定的,并且通过将编码CAVA-PV衣壳的序列替换为编码不同PV株衣壳的序列,显示出可用作骨架以生产与常规疫苗具有相同抗原谱的减毒株的用途。此外,可以将CAVA-PV中鉴定的突变工程化为不同的,甚至是野生型和神经毒性脊髓灰质炎病毒本底菌株,以获得其他CAVA-PV菌株。没有合适的身材

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号